MedUni Wien Researcher of the month, Mai 2021, Dr. Venugopal Gudipati
Inefficient CAR-proximal signaling blunts antigen detection.
Dr. Venugopal Gudipati
"Chimeric antigen receptor (CAR)-T cell therapy is a new and revolutionary therapy against cancer. In a recent study published in Nature Immunology, our HAI colleagues Venugopal Gudipati and Johannes Huppa show that If the tumor antigens are low, CAR-T cells do not initiate intracellular signalling adequately. The results of this study suggest that future CAR designs based on the architecture of the T cell receptor (TCR) might provide much needed improvements in CAR-T cell antigen sensitivity and long-term complete remission rates."
back to: Institute for Hygiene and Applied Immunology